Source: University of California Riverside
Summary: Researchers have discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.
Tumor metastasis is a leading cause of patient morbidity and mortality, and no treatments are currently available that specifically target metastasis formation. Cancer cells depend on a number of oncogenes, like EphA2, to form metastasis, the medical term for cancer spreading from the primary site to other regions in the body, accomplished when cancer cells break away from the primary site, travel through the blood or lymph system, and form new tumors elsewhere in the body. Until now, paclitaxel has only been used to target rapidly dividing cancer cells. The research team from the University of California Riverside was successful in getting the drug to piggyback on 123B9, an agent they devised to target an oncogene called EphA2 (ephrin type-A receptor 2). EphA2 spreads cancer by allowing malignant cells to migrate from the primary tumor into circulation and eventually to adhere to other tissues. The study findings were published in the Journal of Medicinal Chemistry.
The research team found that when 123B9 binds to the extracellular region of the EphA2 receptor expressed in cancer cells, it causes the oncogene to internalize and degrade inside the cell, thus preventing cancer cells from entering circulation and metastasizing. Recent collaborative work between UCR and Cedars-Sinai Medical Center in Los Angeles demonstrated that in animal models of human breast cancer, mice treated with 123B9 that was conjugated with paclitaxel had significantly fewer circulating cancer cells in the blood compared to mice that were not treated or even treated with paclitaxel alone. The study predicts that reducing the number of circulating cancer cells produces less metastasis. Researchers said that the road to a therapeutic for human trials is still long and includes the iterative design and synthesis of more potent and selective agents.
Prof. Maurizio Pellecchia said, “Nonetheless, the proof of concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper support and efforts we could translate our findings into experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic, and ovarian cancers”.
More Information: Ahmed F Salem et al, “A potent EphA2 agonistic peptide-drug conjugate reduces circulating cancer cells and metastases in breast cancer models”, Journal of Medicinal Chemistry (2018). DOI: 10.1021/acs.jmedchem.7b01837